1
|
Dong Q, Fu L, Zhao Y, Du Y, Li Q, Qiu X, Wang E. Rab11a promotes proliferation and invasion through regulation of YAP in non-small cell lung cancer. Oncotarget 2018; 8:27800-27811. [PMID: 28468127 PMCID: PMC5438609 DOI: 10.18632/oncotarget.15359] [Citation(s) in RCA: 43] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2016] [Accepted: 01/09/2017] [Indexed: 12/25/2022] Open
Abstract
Rab11a, an evolutionarily conserved Rab GTPases, plays important roles in intracellular transport and has been implicated in cancer progression. However, its role in human non-small cell lung cancer (NSCLC) has not been explored yet. In this study, we discovered that Rab11a protein was upregulated in 57/122 NSCLC tissues. Rab11a overexpression associated with advanced TNM stage, positive nodal status and poor patient prognosis. Rab11a overexpression promoted proliferation, colony formation, invasion and migration with upregulation of cyclin D1, cyclin E, and downregulation of p27 in NSCLC cell lines. Nude mice xenograft demonstrated that Rab11a promoted in vivo cancer growth. Importantly, we found that Rab11a induced YAP protein and inhibited Hippo signaling. Depletion of YAP abolished the effects of Rab11a on cell cycle proteins and cell proliferation. Furthermore, immunoprecipitation showed that Rab11a interacted with YAP in lung cancer cells. In conclusion, the present study suggestes that Rab11a serves as an important oncoprotein and a regulator of YAP in NSCLC.
Collapse
Affiliation(s)
- Qianze Dong
- Department of Pathology, First Affiliated Hospital and College of Basic Medical Science, China Medical University, Shenyang, China
| | - Lin Fu
- Department of Pathology, First Affiliated Hospital and College of Basic Medical Science, China Medical University, Shenyang, China
| | - Yue Zhao
- Department of Pathology, First Affiliated Hospital and College of Basic Medical Science, China Medical University, Shenyang, China
| | - Yaming Du
- Department of Cardiovascular Thoracic Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China
| | - Qingchang Li
- Department of Pathology, First Affiliated Hospital and College of Basic Medical Science, China Medical University, Shenyang, China
| | - Xueshan Qiu
- Department of Pathology, First Affiliated Hospital and College of Basic Medical Science, China Medical University, Shenyang, China
| | - Enhua Wang
- Department of Pathology, First Affiliated Hospital and College of Basic Medical Science, China Medical University, Shenyang, China
| |
Collapse
|
2
|
Liu L, Zhou XM, Yang FF, Miao Y, Yin Y, Hu XJ, Hou G, Wang QY, Kang J. TRIM22 confers poor prognosis and promotes epithelial-mesenchymal transition through regulation of AKT/GSK3β/β-catenin signaling in non-small cell lung cancer. Oncotarget 2017; 8:62069-62080. [PMID: 28977927 PMCID: PMC5617487 DOI: 10.18632/oncotarget.18911] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Accepted: 05/23/2017] [Indexed: 01/21/2023] Open
Abstract
Expression pattern and biological roles of TRIM22 remains unknown in most human cancers. The present study aims to discover its clinical significance and function in human non-small cell lung cancer (NSCLC). Immunohistochemistry was used to examine TRIM22 expression in 126 cases of NSCLC specimens. TRIM22 protein was upregulated in 70/126 (55.6%) non-small cell lung cancer tissues compared with normal lung tissue. TRIM22 overexpression was associated with advanced TNM stage, positive nodal metastasis and poor prognosis. Plasmid and siRNA transfection were performed in lung cancer cell lines. TRIM22 overexpression promoted proliferation, colony formation and invasion in A549 cells. While its depletion exhibited the opposite effects in H1299 cell line. TRIM22 overexpression promoted cell cycle progression through regulation of cyclin D1, cyclin E and p27. TRIM22 also changed the expression of epithelial to mesenchymal transition (EMT) markers including E-cadherin N-cadherin, Vimentin and Snail. Furthermore, TRIM22 activated PI3K/AKT/GSK3β/β-catenin oncogenic signaling pathways. Treatment with PI3K inhibitor LY294002 and β-catenin siRNA blocked the effects of TRIM22 on EMT in TRIM22-overexpressing cells. In conclusion,TRIM22 serves as an important oncoprotein and a promoter of cell proliferation and invasion through AKT/ GSK3β/β-catenin induced EMT in NSCLC.
Collapse
Affiliation(s)
- Li Liu
- Department of Respiratory Medicine, The First Hospital of China Medical University, Shenyang 110001, China
| | - Xiao-Ming Zhou
- Department of Respiratory Medicine, The Shengjing Hospital of China Medical University, Shenyang 110004, China
| | - Fang-Fei Yang
- Department of Respiratory Medicine, The First Hospital of China Medical University, Shenyang 110001, China
| | - Yuan Miao
- Department of Pathology, The First Hospital and College of Basic Medical Sciences, China Medical University, Shenyang 110001, China
| | - Yan Yin
- Department of Respiratory Medicine, The First Hospital of China Medical University, Shenyang 110001, China
| | - Xue-Jun Hu
- Department of Respiratory Medicine, The First Hospital of China Medical University, Shenyang 110001, China
| | - Gang Hou
- Department of Respiratory Medicine, The First Hospital of China Medical University, Shenyang 110001, China
| | - Qiu-Yue Wang
- Department of Respiratory Medicine, The First Hospital of China Medical University, Shenyang 110001, China
| | - Jian Kang
- Department of Respiratory Medicine, The First Hospital of China Medical University, Shenyang 110001, China
| |
Collapse
|
3
|
Sanz-Santos J, Serra P, Andreo F, Torky M, Centeno C, Morán T, Carcereny E, Fernández E, García-Reina S, Ruiz-Manzano J. Transbronchial and transesophageal fine-needle aspiration using a single ultrasound bronchoscope in the diagnosis of locoregional recurrence of surgically-treated lung cancer. BMC Pulm Med 2017; 17:46. [PMID: 28241873 PMCID: PMC5330131 DOI: 10.1186/s12890-017-0388-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Accepted: 02/22/2017] [Indexed: 12/18/2022] Open
Abstract
Background The present study sought to evaluate the usefulness of EBUS-TBNA in the diagnosis of locoregional recurrence of lung cancer in a cohort of lung cancer patients who were previously treated surgically, and describe our initial experience of EUS-B-FNA in this clinical scenario. Methods We retrospectively studied the clinical records of all patients with a previous surgically-treated lung cancer who were referred to our bronchoscopy unit after suspicion of locoregional recurrence. The diagnostic sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and overall accuracy of EBUS-TBNA for the diagnosis of locoregional recurrence were evaluated. Results Seventy-three patients were included. EBUS-TBNA confirmed malignancy in 40 patients: 34 confirmed to have locoregional recurrence, six had metachronous tumours. Of the 33 patients with non-malignant EBUS-TBNA; 2 had specific non-malignant diseases, 26 underwent radiological follow up and 5 patients underwent surgery. Of the 26 patients who had radiological follow up; 18 remained stable, three presented thoracic radiological progression and 5 presented extrathoracic progression. Of the 5 patients who underwent surgery; 3 had metachronous tumours, one confirmed to be a true negative and one presented nodal invasion. Seven patients underwent EUS-B-FNA, four of them confirmed to have recurrence. The sensitivity, specificity, NPV, PPV and overall accuracy of EBUS-TBNA for the diagnosis of locoregional recurrence were 80.9, 100, 69.2, 100 and 86.6% respectively. Conclusions EBUS-TBNA is an accurate procedure for the diagnosis of locoregional recurrence of surgically-treated lung cancer. EUS-B-FNA combined with EBUS-TBNA broads the diagnostic yield of EBUS-TBNA alone.
Collapse
Affiliation(s)
- José Sanz-Santos
- Pulmonology Department, Hospital Germans Trias i Pujol, Carretera de Canyet S/N. 08916, Badalona, Barcelona, Spain.
| | - Pere Serra
- Pulmonology Department, Hospital Germans Trias i Pujol, Carretera de Canyet S/N. 08916, Badalona, Barcelona, Spain.,Department de Medicina. Universitat Autònoma de Barcelona, Bellaterra, Barcelona, Spain
| | - Felipe Andreo
- Pulmonology Department, Hospital Germans Trias i Pujol, Carretera de Canyet S/N. 08916, Badalona, Barcelona, Spain
| | - Mohamed Torky
- Pulmonology Department, Hospital Germans Trias i Pujol, Carretera de Canyet S/N. 08916, Badalona, Barcelona, Spain
| | - Carmen Centeno
- Pulmonology Department, Hospital Germans Trias i Pujol, Carretera de Canyet S/N. 08916, Badalona, Barcelona, Spain
| | - Teresa Morán
- Catalan Institute of Oncology, Badalona, Barcelona, Spain
| | - Enric Carcereny
- Thoracic Surgery Department, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - Esther Fernández
- Thoracic Surgery Department, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - Samuel García-Reina
- Thoracic Surgery Department, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
| | - Juan Ruiz-Manzano
- Pulmonology Department, Hospital Germans Trias i Pujol, Carretera de Canyet S/N. 08916, Badalona, Barcelona, Spain
| |
Collapse
|